Novo Nordisk's STEP Young trial found 40.4% of treated children moved below the obesity threshold. Learn the clinical reality behind the latest pediatric data.
On September 7, 2026, Novo Nordisk announced topline results from its Phase III STEP Young trial regarding pediatric obesity. The trial evaluated once-weekly subcutaneous semaglutide in 165 children aged 6 to under 12 with obesity. According to the manufacturer, 40.4% of children treated with the medication moved below the obesity threshold after 68 weeks. In contrast, none of the children in the placebo group achieved this transition out of the obesity category.
The medical community defines childhood obesity using age- and sex-specific BMI percentiles rather than standard adult cutoffs. For children, the relevant threshold is a BMI at or above the 95th percentile. Novo Nordisk estimated that 177 million children aged 5 to 19 were living with obesity globally in 2025. The company projects this demographic will reach 228 million by 2040.
The STEP Young trial highlights a shift toward treating obesity as a complex metabolic condition. We know that weight management is never just a matter of willpower. It involves a delicate interaction between appetite, nutrition, daily habits and medical treatment. Both the semaglutide group and the placebo group in this trial received structured lifestyle modifications.
These modifications specifically included guidance for a reduced-calorie diet and increased physical activity. Participants in the treatment arm received a maximum semaglutide dose of either 1.7 mg or 2.4 mg. This dosage was determined by their body weight at the start of the clinical trial. Semaglutide functions alongside these daily routines to support metabolic regulation and appetite control.
Many adults who have experienced yo-yo dieting might view these results as proof of rapid weight loss across all age groups. However, adults should be cautious about applying specific pediatric trial data to general adult populations. The trial involved a very specific pediatric demographic, a specific drug regimen and structured lifestyle care over a 68-week period. WeightRestart emphasizes that sustainable results require a focus on lifelong metabolic health rather than chasing rapid scale victories.
By pairing medication with lifestyle support, researchers acknowledge the full ecosystem of health. Medical interventions provide biological support while patients work on foundational routines like physical activity and sleep. Adults often evaluate these exact metabolic pathways when reviewing tirzepatide versus semaglutide weight loss and safety outcomes. This holistic approach ensures that medication acts as an integrated tool rather than a standalone solution.
When the new class of weight-loss medications started dominating the news, the media reaction was entirely polarized. It was often framed as an absolute cure or a moral failing. Our team saw a huge need for calm and objective reporting. We decided to cover these medications exactly like any other tool by evaluating the clinical data, the benefits and the limitations without any judgment.
The response from our readers showed just how starved people were for facts over feelings. We must apply this same objective lens to the STEP Young trial coverage. The Indian Express reported the headline finding as roughly four in ten children moving below the obesity threshold. However, this coverage often misses the precise statistical nature of the company’s 40.4% figure.
This success rate is based on a product estimand that assumes perfect patient adherence to the medication regimen. It may not reflect the percentage of patients who would achieve this outcome in routine medical care. Real-world treatment often involves missed injections, changing access, and varying family circumstances. Furthermore, the trial focused heavily on children with severe metabolic conditions rather than mild excess weight.
More than 85% of participants had class II or class III severe obesity at baseline. These pediatric definitions correspond to at least 120% or 140% of the 95th BMI percentile. Because the study focused on severe cases, the findings may not generalize directly to children with milder obesity. It is critical to remember that crossing a BMI category does not mean a metabolic condition is permanently resolved.
The STEP Young data adds to a growing body of research regarding younger populations and metabolic treatments. Ania M. Jastreboff is a Yale professor of medicine and pediatrics and director of the Yale Obesity Research Center. She noted that childhood obesity can have both immediate and long-term health effects. She also emphasized that most of the trial participants entered the study with severe obesity.
The U.S. Food and Drug Administration previously approved Wegovy for chronic weight management in adolescents aged 12 and older with obesity. This approval occurred in December 2022. The STEP Young trial specifically addresses a younger demographic than this current adolescent indication. It aims to provide critical data for children starting at age 6.
The trial successfully met its primary endpoint of generating a greater BMI reduction than the placebo at week 68. This mirrors earlier findings from the STEP TEENS study which evaluated older adolescents. The STEP TEENS study reported a 16.1% BMI reduction with semaglutide. In contrast, those receiving a placebo saw their BMI increase by 0.6% over a similar timeframe.
Novo Nordisk stated that the overall safety and tolerability profile was consistent with previous semaglutide trials in adults. The company reported that no new safety concerns were identified during the STEP Young trial. They also identified no safety concerns relating to growth or pubertal development. Martin Holst Lange is Novo Nordisk’s executive vice president, chief scientific officer, and head of research and development.
He said the company viewed semaglutide as potentially useful for children who need medical treatment alongside lifestyle changes. Because these comments represent the manufacturer's perspective, they should be viewed alongside independent clinical consensus. Families must weigh these short-term safety markers against the lack of multi-year treatment data. Clinicians must consider how these medications interact with a child's overall wellbeing and daily habits.
A responsible treatment plan tracks physical function, mental health, eating behaviors, and gastrointestinal symptoms. If you are evaluating how standard care adapts to specific demographics, you can review our insights on how age changes weight loss protocols. Medication should always support sustainable health rather than just rapid changes on a scale.
The available topline release does not provide all the necessary details for a complete clinical assessment. Novo Nordisk has not publicly supplied numerical BMI changes, confidence intervals, p-values, or detailed adverse-event frequencies. The release also does not report whether children remained below the obesity threshold after treatment stopped. This means the durability of the result cannot be determined from the currently available data.
The STEP Young release describes the trial as part of regulatory post-marketing requirements for the semaglutide clinical development program. Detailed STEP Young results are scheduled to be presented at the Obesity Society’s ObesityWeek 2026 meeting. The Obesity Society will host this medical meeting in Washington D.C. from November 14 to 17 in 2026. Independent peer-reviewed publications will eventually offer a much clearer picture of the treatment's true efficacy.
The 68-week duration of the trial provides limited evidence regarding multi-year treatment plans. This relatively short timeframe leaves questions about long-term growth, sustained adherence, and weight maintenance unanswered. The available material does not establish whether the benefits outweighed the risks for every single child in the study. Individual treatment decisions will always depend on personal growth patterns, existing comorbidities, and careful clinician monitoring.
For adults managing their own health, this trial reinforces that obesity requires comprehensive and ongoing medical management. It highlights the importance of combining evidence-based treatments with sustainable lifestyle modifications. The future of metabolic care will demand individualized combinations of nutritional, behavioral, and medical support. You can learn more about sustaining these habits in our article about navigating post-treatment weight regain.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
